| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Oct―13 |
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option |
Sara Ferraro, Irma Convertino, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori |
| 2 |
[GO] |
2023―Aug―24 |
Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants |
Pasquale Pagliano, Annamaria Spera, Carmine Sellitto, Giuliana Scarpati, Veronica Folliero, Ornella Piazza, et al. (+3) Gianluigi Franci, Valeria Conti, Tiziana Ascione |
| 3 |
[GO] |
2023―Jul―17 |
How can artificial intelligence be utilized for de novo drug design against COVID-19 (SARS-CoV-2)? |
Giuseppe Floresta, Chiara Zagni, Vincenzo Patamia, Antonio Rescifina |
| 4 |
[GO] |
2023―May―27 |
The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection |
Vivian Weiwen Xue, Sze Chuen Cesar Wong, Bo Li, William Chi Shing Cho |
| 5 |
[GO] |
2023―Mar―27 |
An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery |
Mahmoud Kandeel |
| 6 |
[GO] |
2023―Feb―01 |
Targeting Viral Proteins for Restraining SARS-CoV-2: Focusing Lens on Viral Proteins Beyond Spike for Discovering New Drug Targets |
Tao Yang, Si Chun Wang, Linyan Ye, Yasen Maimaitiyiming, Hua Naranmandura |
| 7 |
[GO] |
2023―Jan―17 |
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence |
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori |
| 8 |
[GO] |
2022―Dec―12 |
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19) |
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, Giuliana Scarpati, Veronica Folliero, Ornella Piazza, et al. (+3) Gianluigi Franci, Amelia Filippelli, Valeria Conti |
| 9 |
[GO] |
2022―Sep―26 |
How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned? |
E. Sila Ozdemir, Srivathsan V. Ranganathan, Ruth Nussinov |
| 10 |
[GO] |
2022―Apr―01 |
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall |
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, et al. (+2) Massimo Franchini, Daniele Focosi |
| 11 |
[GO] |
2022―Mar―12 |
Perspectives on the design and discovery of α-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go? |
Alessio Nocentini, Clemente Capasso, Claudiu T. Supuran |
| 12 |
[GO] |
2022―Mar―08 |
Antimicrobial peptides: A plausible approach for COVID-19 treatment |
Pooja Rani, Bhupinder Kapoor, Monica Gulati, Atanas G. Atanasov, Qushmua Alzahrani, Reena Gupta |
| 13 |
[GO] |
2022―Jan―24 |
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19 |
Christiana Mantzourani, Sofia Vasilakaki, Velisaria-Eleni Gerogianni, George Kokotos |
| 14 |
[GO] |
2021―Nov―24 |
Fluorescent quantum dots enable SARS-CoV-2 antiviral drug discovery and development |
Kirill Gorshkov, Kimihiro Susumu, Mason Wolak, Eunkeu Oh |
| 15 |
[GO] |
2021―Nov―03 |
Using in vivo animal models for studying SARS-CoV-2 |
Camila B. P. Da Costa, Ana Claudia De Menezes Cruz, Julio Cesar Q Penha, Helena C Castro, Luis E. R. Da Cunha, Norman A Ratcliffe, et al. (+2) Rafael Cisne, Francislene Juliana Martins |
| 16 |
[GO] |
2021―Sep―10 |
The challenges with developing therapeutic monoclonal antibodies for pandemic application |
Andreas H. Laustsen, Markus-Frederik Bohn, Anne Ljungars |
| 17 |
[GO] |
2021―Aug―20 |
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19) |
Pasquale Pagliano, Carmine Sellitto, Giuliana Scarpati, Tiziana Ascione, Valeria Conti, Gianluigi Franci, et al. (+2) Ornella Piazza, Amelia Filippelli |
| 18 |
[GO] |
2021―Jul―26 |
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future |
Marco Tuccori, Irma Convertino, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Elisabetta Fini, Daniele Focosi |
| 19 |
[GO] |
2021―Jun―01 |
How can we accelerate COVID-19 vaccine discovery? |
Giulia Russo, Valentina Di Salvatore, Filippo Caraci, Cristina Curreli, Marco Viceconti, Francesco Pappalardo |
| 20 |
[GO] |
2021―Mar―26 |
Analysis of the SARS-CoV-2-Host Protein Interaction Network Reveals New Biology and Drug Candidates: Focus on the Spike Surface Glycoprotein and the RNA Polymerase |
Esen Sokullu, Maxime Pinard, Marie-Soleil Gauthier, Benoit Coulombe |
| 21 |
[GO] |
2020―Dec―28 |
Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges |
Koippallil Gopalakrishnan Aghila Rani, Mohamad A. Hamad, Dana M. Zaher, Scott McN Sieburth, Navid Madani, Taleb H. Al-Tel |
| 22 |
[GO] |
2020―Dec―19 |
Can drug repurposing strategies be the solution to the COVID-19 crisis? |
Carolina L. Bellera, Manuel Llanos, Melisa E. Gantner, Santiago Rodriguez, Luciana Gavernet, Marcelo Comini, Alan Talevi |
| 23 |
[GO] |
2020―Dec―14 |
Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic? |
Joel Lexchin |
| 24 |
[GO] |
2020―Sep―11 |
Are open-source approaches the most efficient way forward for COVID-19 drug discovery? |
Amer Harky, Vaibhav Mishra, Daniyal Matin Ansari, Naomi Melamed |
| 25 |
[GO] |
2020―Sep―11 |
Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs |
Damiano Cirri, Alessandro Pratesi, Tiziano Marzo, Luigi Messori |
| 26 |
[GO] |
2020―Jun―16 |
Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited! |
Mohamed Boudjelal, Atef Nehdi, Imadul Islam |
